Under the exclusive distribution agreement, DKSH will market and distribute Johnson Matthey’s (JM’s) biocatalysts, heterogeneous and homogenous catalysts to pharmaceutical and fine chemical firms in Japan.
Distributed products will include JM’s metal scavengers, including microporous polymer and irregular silica, used in purification processes.
A Johnson Matthey spokesperson told us pharma companies are developing more targeted and potent active pharmaceutical ingredients (APIs), which have increasingly complex molecular structures.
JM’s catalysts “enables customers to create faster and more sustainable chemistry processes,” we were told.
While JM catalysts have previously been available in Japan, the marking and distribution agreement will extend its presence, the spokesperson told us.
JM has manufacturing facilities around the world, with Taloja, India and Shanghai, China being the centres for catalyst manufacture in Asia.
In June last year, in-PharmaTechnologist reported JM had partnered with Intrexon Corporation to develop peptide active pharmaceutical ingredient (API) production methods.
Three months later, JM entered an agreement with Snapdragon Chemistry, to offer a continuous manufacturing-based API production service.